2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130326
    RAPTA-C 372948-28-2 99.30%
    RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model.
    RAPTA-C
  • HY-130353
    Desethylamiodarone hydrochloride 96027-74-6 99.0%
    Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes. Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC50 of 19.1 μM.
    Desethylamiodarone hydrochloride
  • HY-130368
    W-7 65595-90-6 99.35%
    W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias.
    W-7
  • HY-13443B
    Exendin-4-Lys-azide TFA 99.84%
    Exendin-4-Lys-azide TFA (Compound Ex40) is an azide derivative of Exendin-4-Lys-azide, Exendin-4, which can be used for coupling/click chemistry.
    Exendin-4-Lys-azide TFA
  • HY-135356
    m-Nifedipine 21881-77-6
    m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.
    m-Nifedipine
  • HY-135363
    Valsartan Ethyl Ester 1111177-30-0 99.70%
    Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure.
    Valsartan Ethyl Ester
  • HY-135910
    3,4-Dehydro Cilostazol 73963-62-9 98.10%
    3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study.
    3,4-Dehydro Cilostazol
  • HY-137818
    SR19881 2213490-89-0 99.30%
    SR19881 is a potent dual agonist of ERRγ and ERRβ, with EC50 values of 0.39 and 0.63 μM, respectively.
    SR19881
  • HY-137976
    Penehyclidine hydrochloride 151937-76-7 ≥99.0%
    Penehyclidine (Penequinine) hydrochloride, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine hydrochloride activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine hydrochloride can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation.
    Penehyclidine hydrochloride
  • HY-138201
    IM-93 1173657-73-2 99.00%
    IM-93 inhibits ferroptosis and NETosis with an IC< sub>50 of 0.45 µM for cell death inhibition.
    IM-93
  • HY-139419
    Bimatoprost grenod 1194396-71-8 99.10%
    Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue. Bimatoprost grenod effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. Bimatoprost grenod can be used for the research of cular hypertension and glaucoma.
    Bimatoprost grenod
  • HY-141581
    Lyso-PAF C-18 74430-89-0 99.74%
    Lyso-PAF C-18 is an intermediate for the synthesis of C18-PAF (HY-130345). It has an easily substituted "Lyso-PAF" structure and is easy to purify and has high yield. C18-PAF is a ligand for platelet-activating factor and PAF G protein-coupled receptor (PAFR) and has renovasodilator properties and antihypertensive lipid properties.
    Lyso-PAF C-18
  • HY-141714
    SBC-115337 423148-46-3 98.02%
    SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC50 value of 0.5 μM.
    SBC-115337
  • HY-142059
    PDE5-IN-4 224788-36-7 99.60%
    PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure.
    PDE5-IN-4
  • HY-14252A
    Milrinone lactate 100286-97-3 98.76%
    Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock.
    Milrinone lactate
  • HY-144652
    IDO1-IN-19 2328099-11-0 98.82%
    IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases.
    IDO1-IN-19
  • HY-145197
    MPO-IN-3 1435469-45-6 99.17%
    MPO-IN-3 is a potent myeloperoxidase (MPO) inhibitor (WO2013068875A1, example 191). Myeloperoxidase (MPO) is a heme-containing enzyme belonging to the peroxidase superfamily.
    MPO-IN-3
  • HY-14622B
    Necrostatin 2 (S enantiomer) 852391-20-9 99.76%
    Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2 (HY-14622). Necrostatin 2 S enantiomer inhibits TNF-α-induced necroptosis in Jurkat T cells. Necrostatin 2 S enantiomer can be used for the research of ischemic brain injury (stroke).
    Necrostatin 2 (S enantiomer)
  • HY-14928A
    Lobeglitazone sulfate 763108-62-9 99.63%
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties.
    Lobeglitazone sulfate
  • HY-149922
    DKI5 1101130-96-4 98.12%
    DKI5, also known as (E)-N’-benzylidenehydrazinecarbothiohydrazide, is a LOX-1 inhibitor with an IC50 value of 22.5 μM.
    DKI5
Cat. No. Product Name / Synonyms Application Reactivity